G-15: G Protein-Coupled Estrogen Receptor Antagonist in Research

Principle Overview: Precision Interrogation of Estrogen Signaling

G-15 (CAS 1161002-05-6) is a next-generation tool compound that enables selective inhibition of G protein-coupled estrogen receptor 30 (GPR30, also known as GPER), a membrane-bound estrogen receptor distinct from classical nuclear ERα and ERβ. Unlike traditional estrogen receptor modulators, G-15 exhibits a Ki of ~20 nM for GPR30 and demonstrates negligible activity against ERα/ERβ even at high concentrations, making it a gold-standard antagonist for dissecting GPR30-specific signaling (product information). GPR30, localized primarily in the endoplasmic reticulum, mediates rapid intracellular responses to estrogenic ligands—including calcium flux, PI3K/Akt pathway engagement, and downstream proliferative or neurological effects.

Recent research has highlighted the pivotal role of GPR30 in complex neurobiological processes such as neuropathic pain, cell proliferation, and synaptic plasticity, as well as its utility in translational models of cancer and immune function (complementary review).

Step-By-Step Workflow: Applied Use-Cases for G-15

G-15's solubility profile, selectivity, and robust antagonism make it a versatile tool for both in vitro and in vivo models of estrogen signaling research. Below is a streamlined workflow optimized for common applications:

1. Stock Solution Preparation: Dissolve G-15 in DMSO at concentrations ≥37 mg/mL. Warm the solution to 37 °C or use an ultrasonic bath to facilitate dissolution. Avoid water or ethanol, as G-15 is insoluble in these solvents (product page).
2. Cellular Assays: For intracellular calcium mobilization assays and PI3K/Akt pathway modulation studies, dilute the stock to working concentrations (typically 100–500 nM final). Preincubate cells with G-15 at least 30 minutes before estrogenic ligand or G-1 stimulation to achieve maximal GPR30 blockade.
3. In Vivo Administration: For studies in animal models (e.g., spatial learning in ovariectomized rats or neuropathic pain models), G-15 may be administered via intrathecal or intraperitoneal injection. Dosing regimens typically range from 1–10 mg/kg, tailored to the specific behavioral or molecular endpoint. Solutions should be freshly prepared from DMSO stocks and diluted in compatible vehicles immediately before use to prevent degradation.

Protocol Parameters

• Stock concentration: Prepare G-15 at ≥37 mg/mL in DMSO; warm to 37 °C or use an ultrasonic bath to dissolve fully.
• Cellular assay working concentration: Use 100–500 nM G-15; preincubate for 30–60 minutes prior to ligand challenge.
• In vivo dosing: Administer 1–10 mg/kg via intrathecal or intraperitoneal route; dilute immediately before injection and use within 2 hours to maintain compound integrity.

Key Innovation from the Reference Study

In the landmark study by Chen, Wu, Xie et al. (eLife 2024), G-15 was leveraged to provide the first direct evidence that GPR30 in spinal cholecystokinin-positive (CCK+) neurons acts as a switch for neuropathic pain modulation. The authors demonstrated that GPR30 expression is upregulated in chronic constriction injury (CCI) models, and that selective antagonism of GPR30 by G-15 reverses mechanical allodynia and synaptic hyperexcitability in these neurons. Notably, chemogenetic inhibition or activation studies showed that the presence of GPR30 in CCK+ neurons is both necessary and sufficient for neuropathic pain states, establishing GPR30 as a molecular target for analgesic intervention.

Practical assay translation: This finding guides the experimental workflow in several ways. For studies investigating pain circuitry or synaptic transmission, pre-treatment with G-15 enables investigators to isolate GPR30-dependent events from classical estrogen receptor effects, reducing confounding and sharpening mechanistic insights. The same workflow can be adapted for other GPR30-expressing systems, such as tumor proliferation or neurodevelopmental models.

Comparative Advantages and Advanced Applications

Compared to broad-spectrum ER antagonists, G-15 offers unique advantages in selectivity and performance:

• Superior specificity: G-15's minimal off-target activity toward ERα/ERβ (APExBIO data) allows for unambiguous attribution of observed effects to GPR30 signaling.
• Robust inhibition of calcium mobilization: In cellular models, G-15 inhibits G-1–induced calcium mobilization with an IC₅₀ of ~185 nM, supporting quantitative assessment in calcium flux assays and PI3K/Akt pathway modulation studies.
• In vivo behavioral modulation: The ability of G-15 to impair spatial learning in ovariectomized rats (per APExBIO) and reverse neuropathic pain phenotypes (reference study) makes it an ideal probe for neurobiological and behavioral research.
• Workflow extension: G-15 has been used to dissect GPR30’s role in osteoblast differentiation and tumor proliferation, as outlined in the network pharmacology review—highlighting its cross-disciplinary impact.

Overall, G-15 enables advanced mechanistic studies, supporting both molecular dissection and translational research in pain, cancer, and developmental biology.

Troubleshooting and Optimization Tips

• Solubility issues: If G-15 does not fully dissolve in DMSO, increase temperature to 37 °C and use brief ultrasonication. Avoid repeated freeze–thaw cycles to preserve chemical integrity.
• Compound stability: Prepare aliquots of stock solution and store at −20 °C. Use thawed stocks within 2 weeks; avoid extended exposure to light or ambient temperature to minimize degradation.
• Vehicle controls: Always match DMSO content in vehicle controls (typically ≤0.1% final concentration in cell culture) to account for potential solvent effects.
• Non-specific effects: At concentrations >1 µM, monitor for off-target responses, though G-15 shows minimal ERα/ERβ interaction even at these levels (product page).
• Assay sensitivity: For calcium imaging or phosphorylation readouts, titrate G-15 across a range (100–500 nM) to determine the optimal dose for your specific cell type and endpoint.

Interlinking with Existing Literature

This workflow guide extends and complements several recent resources:

• G-15: Selective GPR30 Antagonist for Precision Estrogen S...—This review offers a broad overview of G-15’s utility in neurobiology and immune modulation, complementing the present article’s focus on pain circuitry and behavioral endpoints.
• G-15 Antagonist: Advanced Insights for GPR30 Signaling Research—Provides advanced protocol design and translational perspectives, contrasting with the current workflow’s emphasis on troubleshooting and direct assay optimization.
• Strategic Dissection of GPR30: G-15’s Impact on Translational Research—Focuses on G-15’s applications in bone and cancer studies, which are extended here to encompass neurological and pain models as defined in the reference study.

Future Outlook: Implications and Next Steps

Findings from the eLife 2024 study underscore a paradigm shift in neuropathic pain research: GPR30 is a critical molecular switch in spinal CCK+ neurons, modulating pain sensitivity and synaptic excitability. By leveraging G-15 as a selective G protein-coupled estrogen receptor antagonist, researchers can now target this pathway with unprecedented precision, paving the way for new therapeutic strategies in chronic pain. Additionally, the workflows and troubleshooting strategies outlined here are readily adaptable to other GPR30-expressing systems in oncology and developmental neurobiology.

As the field matures, further studies using G-15 will be essential for clarifying GPR30’s role in diverse physiological and pathological contexts, from synaptic plasticity to hormone-responsive cancers. APExBIO continues to support this research frontier by providing high-quality G-15 and technical guidance for assay optimization.